PNA(PR2) is a peptide nucleic acid (PNA) complementary to a sequence of the viral protease-encoding gene, effective in blocking HIV release, when used at high doses. Erythrocytes (RBC) were used to target PNA(PR2) to the macrophage compartment. The antiviral activity was assessed in human HIV-infected macrophages both as inhibition of p24 production and reduction of HIV DNA content. PNA(PR2), either added to the medium at a concentration of 100 microM or loaded into RBC at about 40 microM, inhibited p24 production approximately 80% compared with infected samples and reduced HIV DNA content by 83% and 90%, respectively. The results show that (1) a stronger anti-HIV effect is achievable with higher doses of PNA(PR2), both when given free and encapsulated into RBC; (2) the antiviral effect obtained by free PNA(PR2) at a concentration of 100 microM is achievable by encapsulating it into RBC at a concentration of 40 microM, suggesting that RBC can be used as a delivery system to increase the antisense effect of PNA(PR2).

Fraternale, A., Paoletti, M., Casabianca, A., Orlandi, C., Millo, E., Balestra, E., et al. (2009). Erythrocytes as carriers of antisense PNA addressed against HIV-1 gag-pol transframe domain. JOURNAL OF DRUG TARGETING, 17(4), 278-285 [10.1080/10611860902737474].

Erythrocytes as carriers of antisense PNA addressed against HIV-1 gag-pol transframe domain

BALESTRA, EMANUELA;PERNO, CARLO FEDERICO;
2009-05-01

Abstract

PNA(PR2) is a peptide nucleic acid (PNA) complementary to a sequence of the viral protease-encoding gene, effective in blocking HIV release, when used at high doses. Erythrocytes (RBC) were used to target PNA(PR2) to the macrophage compartment. The antiviral activity was assessed in human HIV-infected macrophages both as inhibition of p24 production and reduction of HIV DNA content. PNA(PR2), either added to the medium at a concentration of 100 microM or loaded into RBC at about 40 microM, inhibited p24 production approximately 80% compared with infected samples and reduced HIV DNA content by 83% and 90%, respectively. The results show that (1) a stronger anti-HIV effect is achievable with higher doses of PNA(PR2), both when given free and encapsulated into RBC; (2) the antiviral effect obtained by free PNA(PR2) at a concentration of 100 microM is achievable by encapsulating it into RBC at a concentration of 40 microM, suggesting that RBC can be used as a delivery system to increase the antisense effect of PNA(PR2).
mag-2009
Pubblicato
Rilevanza internazionale
Articolo
Sì, ma tipo non specificato
Settore MED/07 - MICROBIOLOGIA E MICROBIOLOGIA CLINICA
English
Con Impact Factor ISI
Macrophages; Young Adult; Drug Delivery Systems; Anti-HIV Agents; Dose-Response Relationship, Drug; Oligonucleotides, Antisense; Humans; Erythrocytes; Peptide Nucleic Acids; HIV Core Protein p24; HIV-1; Fusion Proteins, gag-pol; gag Gene Products, Human Immunodeficiency Virus; DNA, Viral; Drug Carriers
Fraternale, A., Paoletti, M., Casabianca, A., Orlandi, C., Millo, E., Balestra, E., et al. (2009). Erythrocytes as carriers of antisense PNA addressed against HIV-1 gag-pol transframe domain. JOURNAL OF DRUG TARGETING, 17(4), 278-285 [10.1080/10611860902737474].
Fraternale, A; Paoletti, M; Casabianca, A; Orlandi, C; Millo, E; Balestra, E; Damonte, G; Perno, Cf; Magnani, M
Articolo su rivista
File in questo prodotto:
Non ci sono file associati a questo prodotto.

Questo articolo è pubblicato sotto una Licenza Licenza Creative Commons Creative Commons

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/28873
Citazioni
  • ???jsp.display-item.citation.pmc??? 5
  • Scopus ND
  • ???jsp.display-item.citation.isi??? 12
social impact